NRXS Earnings

NRXS reported its FY2025Q2 earnings on 2025-08-12, showcasing a revenue of 894.09K against an estimate of 983.62K, resulting in a -9.1% surprise. The EPS was -0.22, surpassing the expected -0.23 by 4.35%. The stock experienced a 2.47% price change on the earnings day and a -0.82% change over the next five days, reflecting market reactions to the results.

Following NRXS's FY2025Q2 earnings announcement on 2025-08-12, the stock price moved by 2.47% on the day of the release. Over the subsequent five days, it saw a -0.82% change. Historically, NRXS's stock price tends to shift by an average of 1.27% in the 10 days leading up to earnings and -1.05% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate NRXS's annual revenue to reach 1.10M, while the EPS is projected at -0.21. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NRXS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NRXS's stock price typically moves by 1.27% in the 10 days before its earnings and -1.05% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.21 and revenue of 1.10M.

The earnings call presented mixed signals. While there's optimism around future revenue growth and the new CPT code, immediate financial performance showed declining margins and increased losses. The Q&A revealed strong adoption among some hospitals but also highlighted barriers like prior authorization delays and unclear guidance. The lack of specific revenue guidance and increased operating expenses adds uncertainty. Overall, the strategic plans for 2026 seem positive, but current challenges temper immediate stock price impact, leading to a neutral sentiment.